We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 4, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Zai Lab Ltd. (ZLAB - Free Report) , Li Auto Inc. (LI - Free Report) , Dingdong (Cayman) Ltd. (DDL - Free Report) , Autohome Inc. (ATHM - Free Report) and JD.com, Inc. (JD - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Why China Stocks Are Surging This Week
Amidst all the economic uncertainty this week, stocks of companies that are based in China are doing really well.
Of all these stocks, I've picked five that you can see in the chart below. Zai Lab Ltd. is up 23.1%,Li Auto Inc. up 19.8%, Dingdong (Cayman) Ltd. up 14.4%, Autohome Inc. up 10.1% and JD.com, Inc. up 6.8%.
This obviously can't be related to Xi's election win because that was last week. Moreover, more than one commentator has said how he is pretty much a dictator, going after any company or its management if they don't subscribe to his worldview or strictly follow orders. There are also some big negatives, such as the U.S.-China decoupling (which has been going on for a while now), slowing economic growth and COVID-related shutdowns.
Rumors that the government could be easing COVID restrictions may have lifted the shares.
Another possible explanation for the optimism around China stocks (and it is across a wide swathe of industries) could be the high inflation and impending recession that U.S.-based companies are exposed to. U.S. markets are at a heightened state of volatility not only because the fears of a recession are growing larger, but also because of the Fed's hawkishness that continues to raise borrowing costs.
The Fed's statement yesterday suggests an incrementally cautious approach to future rate hikes, which makes sense given that we are about 8 months from the first hike and it normally takes 9-12 months to get a sense of the impact on the economy. So we are getting there. Future hikes might depend on a better assessment of the economic situation.
However, Fed chair Powell clearly doesn't want to enthuse anyone, because that could have the opposite effect. So he cautioned that it is "very premature" to talk about a pivot. The Fed may be considering the cumulative effect of its tightening measures, but that would probably lead to a 50 bp hike next time rather than a 75 bp hike. Therefore, it continues to look like things have to get far more painful before they get better.
Other reasons could be company-specific, affecting each individual stock differently:
Zai Lab develops and commercializes therapies to treat cancer, autoimmune disorders, infectious diseases and psychiatric disorders primarily in Mainland China and Hong Kong. The company, which is slated to report third-quarter results on Nov 9, has grown its revenues around 200% over the last two years. Since it is in the business of developing drugs, losses are not considered exceptional in the initial years, and the company is investing in building fixed assets and inventory.
Although profits are still some years away, the Zacks Consensus Estimates for 2022 and 2023 indicate a 38.9% improvement in the situation this year on revenue growth of 45.4%. The following year, Zai Lab is expected to improve its profitability by 12.9% on revenue growth of 62.3%.
While monthly deliveries coming out of Chinese EV makers were not exciting, they remained substantially higher on a year-over-year basis. Li Auto saw its October deliveries rise 31% from last year while dropping 13% from September. If COVID restrictions are truly relaxed, the company may be able to resume regular production, which would also boost deliveries. Analysts are looking for revenue growth of 67.6% this year and 70.5% in the next. losses are expected to increase 323.1% this year with Li storming to profits in the next.
The reopening is also proving positive for ecommerce platform Dingdong. The company sells fresh produce, meat, seafood, prepared food, and other food products, such as dairy and bakery products, snacks, oil, seasonings and beverages in China. In the last quarter, it reported strong double-digit GMV and revenue growth with better conversions, as more cities started opening up. The attention to quality and range, scale of operations and greater efficiencies are expected to generate breakeven results in December. Its next earnings report is on Nov 21.
Analysts currently forecast 89.3% earnings growth this year on 16.6% revenue growth. Next year, revenue and earnings are expected to grow an additional 17.1% and 93.0%, respectively.
Autohome, which reports today, offers interactive content and tools through ecommerce websites and apps. Users can use these to research the new or used cars they are looking to purchase. It also provides a range of services and generates revenue through advertising. The company has gone through a tough period as supply chain concerns limited the new cars on offer, which also lowered traffic. However, easing supply chains are leading to greater optimism about the availability of cars, which is expected to translate to stronger results at the company.
Analysts are looking for both revenue and earnings to decline a respective 14.5% and 34.3% this year. But they expect around 7% revenue growth and 8.6% earnings growth in 2023.
JD.com provides electronic and general merchandise and supply chain solutions in mainland China. The rise in share prices may simply be attributed to ongoing volatility, as there was a sharp decline in the last week of October, followed immediately by a jump and then another fall, before another rise. There is a good amount of uncertainty for a company like JD because of the way China treated Alibaba and the general crackdown on Chinese tech companies of late.
Analysts are currently modestly optimistic about JD's prospects. They're looking for revenue growth of 1.5% and 14.9% in 2022 and 2023, respectively. Earnings growth is expected to be stronger, at a respective 31.4% and 21.6%. The company will report on Nov 17, after which we'll know more.
ZLAB and LI shares carry a Zacks Rank #3 (Hold), DDL shares a Zacks Rank #1 (Strong Buy), ATHM shares a Zacks Rank of #4 (Sell) and JD #2 (Buy).
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com
For Immediate Release
Chicago, IL – November 4, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Zai Lab Ltd. (ZLAB - Free Report) , Li Auto Inc. (LI - Free Report) , Dingdong (Cayman) Ltd. (DDL - Free Report) , Autohome Inc. (ATHM - Free Report) and JD.com, Inc. (JD - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Why China Stocks Are Surging This Week
Amidst all the economic uncertainty this week, stocks of companies that are based in China are doing really well.
Of all these stocks, I've picked five that you can see in the chart below. Zai Lab Ltd. is up 23.1%,Li Auto Inc. up 19.8%, Dingdong (Cayman) Ltd. up 14.4%, Autohome Inc. up 10.1% and JD.com, Inc. up 6.8%.
This obviously can't be related to Xi's election win because that was last week. Moreover, more than one commentator has said how he is pretty much a dictator, going after any company or its management if they don't subscribe to his worldview or strictly follow orders. There are also some big negatives, such as the U.S.-China decoupling (which has been going on for a while now), slowing economic growth and COVID-related shutdowns.
Rumors that the government could be easing COVID restrictions may have lifted the shares.
Another possible explanation for the optimism around China stocks (and it is across a wide swathe of industries) could be the high inflation and impending recession that U.S.-based companies are exposed to. U.S. markets are at a heightened state of volatility not only because the fears of a recession are growing larger, but also because of the Fed's hawkishness that continues to raise borrowing costs.
The Fed's statement yesterday suggests an incrementally cautious approach to future rate hikes, which makes sense given that we are about 8 months from the first hike and it normally takes 9-12 months to get a sense of the impact on the economy. So we are getting there. Future hikes might depend on a better assessment of the economic situation.
However, Fed chair Powell clearly doesn't want to enthuse anyone, because that could have the opposite effect. So he cautioned that it is "very premature" to talk about a pivot. The Fed may be considering the cumulative effect of its tightening measures, but that would probably lead to a 50 bp hike next time rather than a 75 bp hike. Therefore, it continues to look like things have to get far more painful before they get better.
Other reasons could be company-specific, affecting each individual stock differently:
Zai Lab develops and commercializes therapies to treat cancer, autoimmune disorders, infectious diseases and psychiatric disorders primarily in Mainland China and Hong Kong. The company, which is slated to report third-quarter results on Nov 9, has grown its revenues around 200% over the last two years. Since it is in the business of developing drugs, losses are not considered exceptional in the initial years, and the company is investing in building fixed assets and inventory.
Although profits are still some years away, the Zacks Consensus Estimates for 2022 and 2023 indicate a 38.9% improvement in the situation this year on revenue growth of 45.4%. The following year, Zai Lab is expected to improve its profitability by 12.9% on revenue growth of 62.3%.
While monthly deliveries coming out of Chinese EV makers were not exciting, they remained substantially higher on a year-over-year basis. Li Auto saw its October deliveries rise 31% from last year while dropping 13% from September. If COVID restrictions are truly relaxed, the company may be able to resume regular production, which would also boost deliveries. Analysts are looking for revenue growth of 67.6% this year and 70.5% in the next. losses are expected to increase 323.1% this year with Li storming to profits in the next.
The reopening is also proving positive for ecommerce platform Dingdong. The company sells fresh produce, meat, seafood, prepared food, and other food products, such as dairy and bakery products, snacks, oil, seasonings and beverages in China. In the last quarter, it reported strong double-digit GMV and revenue growth with better conversions, as more cities started opening up. The attention to quality and range, scale of operations and greater efficiencies are expected to generate breakeven results in December. Its next earnings report is on Nov 21.
Analysts currently forecast 89.3% earnings growth this year on 16.6% revenue growth. Next year, revenue and earnings are expected to grow an additional 17.1% and 93.0%, respectively.
Autohome, which reports today, offers interactive content and tools through ecommerce websites and apps. Users can use these to research the new or used cars they are looking to purchase. It also provides a range of services and generates revenue through advertising. The company has gone through a tough period as supply chain concerns limited the new cars on offer, which also lowered traffic. However, easing supply chains are leading to greater optimism about the availability of cars, which is expected to translate to stronger results at the company.
Analysts are looking for both revenue and earnings to decline a respective 14.5% and 34.3% this year. But they expect around 7% revenue growth and 8.6% earnings growth in 2023.
JD.com provides electronic and general merchandise and supply chain solutions in mainland China. The rise in share prices may simply be attributed to ongoing volatility, as there was a sharp decline in the last week of October, followed immediately by a jump and then another fall, before another rise. There is a good amount of uncertainty for a company like JD because of the way China treated Alibaba and the general crackdown on Chinese tech companies of late.
Analysts are currently modestly optimistic about JD's prospects. They're looking for revenue growth of 1.5% and 14.9% in 2022 and 2023, respectively. Earnings growth is expected to be stronger, at a respective 31.4% and 21.6%. The company will report on Nov 17, after which we'll know more.
ZLAB and LI shares carry a Zacks Rank #3 (Hold), DDL shares a Zacks Rank #1 (Strong Buy), ATHM shares a Zacks Rank of #4 (Sell) and JD #2 (Buy).
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.